摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,5'-(1,4-phenylene)bis(7-amino-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile) | 1202777-64-7

中文名称
——
中文别名
——
英文名称
5,5'-(1,4-phenylene)bis(7-amino-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile)
英文别名
5,5'-(1,4-phenylene)bis(7-amino-2,4-dioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile);7-amino-5-[4-(7-amino-6-cyano-2,4-dioxo-1,5-dihydropyrano[2,3-d]pyrimidin-5-yl)phenyl]-2,4-dioxo-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile
5,5'-(1,4-phenylene)bis(7-amino-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile)化学式
CAS
1202777-64-7
化学式
C22H14N8O6
mdl
——
分子量
486.403
InChiKey
TZSAEGYPAOVBDM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.12
  • 重原子数:
    36.0
  • 可旋转键数:
    2.0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    249.52
  • 氢给体数:
    6.0
  • 氢受体数:
    10.0

反应信息

  • 作为产物:
    描述:
    巴比妥酸对苯二甲醛丙二腈 在 1,1'-(butane-1,4-diyl)bis(1H-imidazol-3-ium) hydrogen sulfate 作用下, 以 为溶剂, 反应 0.25h, 以90%的产率得到5,5'-(1,4-phenylene)bis(7-amino-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile)
    参考文献:
    名称:
    引入了两种新的基于咪唑的双阳离子布朗斯台德酸性离子液体,并比较了它们在巴比妥酸衍生物合成中的催化活性†
    摘要:
    在本文中,报道了制备双咪唑硫酸氢盐和双咪唑高氯酸盐作为两种新的基于咪唑的双阳离子布朗斯台德酸性离子液体。通过FT-IR,质谱,NMR光谱和pH滴定法进行表征后,研究了这些试剂在促进5-亚芳基巴比妥酸和吡喃并[2,3- d ]嘧啶酮衍生物的合成中的适用性。这些方法具有一些优点,例如易于制备催化剂,简单的后处理步骤,短的反应时间,优异的产率以及在反应的所有步骤中使用非有机溶剂以及催化剂的良好可重复使用性。
    DOI:
    10.1039/c8nj01179f
点击查看最新优质反应信息

文献信息

  • Verjuice as a green and bio-degradable solvent/catalyst for facile and eco-friendly synthesis of 5-arylmethylenepyrimidine-2,4,6-trione, pyrano[2,3-d]pyrimidinone and pyrimido[4,5-d]pyrimidinone derivatives
    作者:Niloufar Safari、Farhad Shirini、Hassan Tajik
    DOI:10.1007/s13738-018-1565-y
    日期:2019.4
    of the synthesis of 5-arylmethylenepyrimidine-2,4,6-triones, via Knovenagel condensation reaction between barbituric or thiobarbituric acid and aldehydes. Verjuice is also employed for the effective synthesis of pyrano[2,3-d]pyrimidinone derivatives via a three-component reaction of barbituric acid or its thio analogue, aldehydes and malononitrile. In the same way, pyrimido[4,5-d]pyrimidinone derivatives
    Verjuice(未成熟的葡萄汁)是一种有机酸的天然混合物,可通过pH值和TGA分析鉴定,可通过Knovenagel缩合有效地用于促进5-芳基亚甲基嘧啶-2,4,6-三酮的合成。巴比妥酸巴比妥酸与醛之间的反应。Verjuice还用于通过巴比妥酸或其代类似物,醛和丙二腈的三组分反应有效合成喃并[2,3- d ]嘧啶酮衍生物。同样,嘧啶基[4,5- d]嘧啶酮衍生物可简单地通过巴比妥酸,醛与硫脲在果汁中的反应来制备。这种绿色方法学具有显着的优势,包括操作简单,可接受的反应时间,易于后处理,高收率,避免在反应和后处理过程中使用任何昂贵的起始原料,挥发性和有害有机溶剂以及使用天然,低成本,可重复使用且可生物降解的催化剂。
  • Synthesis of Tetrahydrobenzo[<i>b</i>]pyran and Pyrano[2, 3-<i>d</i>]pyrimidinone Derivatives Using Fe<sub>3</sub>O<sub>4</sub>@Ph-PMO-NaHSO<sub>4</sub> as a New Magnetically Separable Nanocatalyst
    作者:Mahdieh Haghighat、Farhad Shirini、Mostafa Golshekan
    DOI:10.1166/jnn.2019.16032
    日期:2019.6.1

    Immobilized NaHSO4 on core/shell phenylene bridged periodic mesoporous organosilica magnetic nanoparticles (Fe3O4@Ph-PMO-NaHSO4) as a new acidic magnetically separable nanocatalyst was successfully prepared in three steps: (i) preparation of Fe3O4 nanoparticles by a precipitation method, (ii) synthesis of an organic–inorganic periodic mesoporous organosilica structure with phenyl groups on the surface of Fe3O4 magnetic nanoparticles (MNPs) and (iii) finally adsorption of NaHSO4 on periodic mesoporous organosilica (PMO) network. The prepared organic–inorganic magnetic reagent was characterized by Fourier transform infrared spectroscopy (FT-IR), X-ray powder diffraction (XRD), transmission electron microscopy (TEM), N2 adsorption–desorption and energy-dispersive X-ray (EDX) techniques. Finally, it was used as a reusable and new catalyst to promote the synthesis of tetrahydrobenzo[b]pyran and pyrano[2,3-d]pyrimidinone derivatives as important biologically active compounds. Eco-friendly protocol, high yields, short reaction times and easy and quick isolation of the products are the main advantages of this procedure.

    在核/壳苯基桥联周期性介孔有机磁性纳米颗粒(Fe3O4@Ph-PMO-NaHSO4)上固定化的NaHSO4作为一种新型酸性磁性可分离纳米催化剂成功地通过三个步骤制备而成:(i)通过沉淀法制备 纳米颗粒,(ii)合成具有苯基团的有机-无机周期性介孔有机结构,将其覆盖在 磁性纳米颗粒(MNPs)表面,(iii)最后将NaHSO4吸附在周期性介孔有机(PMO)网络上。制备的有机-无机磁性试剂通过傅里叶变换红外光谱(FT-IR)、X射线粉末衍射(XRD)、透射电子显微镜(TEM)、N2吸附-脱附和能谱X射线(EDX)技术进行表征。最后,它被用作可重复使用的新型催化剂,促进四氢苯并[b]喃和喃并[2,3-d]嘧啶酮衍生物的合成,这些是重要的生物活性化合物。环保的方案、高产率、短反应时间以及产品的易于快速分离是该程序的主要优点。
  • Introduction of organic/inorganic Fe<sub>3</sub>O<sub>4</sub>@MCM-41@Zr-piperazine magnetite nanocatalyst for the promotion of the synthesis of tetrahydro-4<i>H</i>-chromene and pyrano[2,3-<i>d</i>]pyrimidinone derivatives
    作者:Reyhaneh Pourhasan-Kisomi、Farhad Shirini、Mostafa Golshekan
    DOI:10.1002/aoc.4371
    日期:2018.7
    highly dispersed in the tetrahedral environment of silica framework and piperazine is successfully attached to the surface of the nanocatalyst in connection with zirconium. The prepared nanosized reagent (10–30 nm), shows excellent catalytic activity in the synthesis of tetrahydro‐4H‐chromene and pyrano[2,3‐d]pyrimidinone derivatives. All reactions are performed under mild and completely heterogeneous
    哌嗪修饰的Fe 3 O 4 @ MCM-41 @ Zr-MNPs易于制备,并使用傅里叶变换红外光谱(FT-IR),X射线粉末衍射(XRD),N 2吸附-解吸,透射电子显微镜进行表征( TEM),能量色散X射线(EDX),振动样品磁力法(VSM)和热重分析(TGA)技术。表征结果表明,高度分散在二氧化硅骨架和哌嗪的四面体环境中的Zr可以成功地附着在与相关的纳米催化剂表面。制备的纳米级试剂(10–30 nm)在四氢-4 H-色烯和喃[2,3- d]嘧啶酮衍生物。所有反应均在温和且完全异质的反应条件下进行,且反应时间短。另一方面,由于其超顺磁性,该催化剂可通过施加外部磁场容易地分离并重复使用多次。
  • Three-component synthesis of 4<i>H</i>-pyran scaffolds accelerated by a gabapentin-based natural deep eutectic solvent
    作者:Meysam Alipour Khoshdel、Farhad Shirini、Mohaddeseh Safarpoor Nikoo Langarudi、Mehdi Zabihzadeh、Mohammad Biglari
    DOI:10.1039/d0nj05342b
    日期:——
    catalyst for the synthesis of 4H-pyran scaffolds such as tetrahydrobenzo[b]pyran and pyrano[2,3-d]pyrimidinone(thione) derivatives. The use of inexpensive and bio-compatible reagents for the synthesis of the catalyst, a simple and green procedure for the preparation of the catalyst and products, short reaction times, high yields of the products, and applicability to large-scale synthesis are the prominent
    在最近的有机合成中,对环境无害的合成方法的发展引起了越来越多的关注。作为这一概念的一部分,我们的小组使用加巴喷丁氯化胆碱合成了一种新型的天然深共熔溶剂(NADES)。在通过FTIR,1 H和13 C NMR以及质谱进行表征后,所制备的NADES被用作合成4 H-喃骨架如四氢苯并[ b ]喃和喃并[2,3- d ]的有效催化剂。]嘧啶酮(酮)衍生物。廉价的和生物相容性试剂用于催化剂的合成,用于催化剂和产物的制备的简单且绿色的过程,短的反应时间,产物的高产率以及适用于大规模合成是突出的问题。该协议的功能。而且,该催化剂可以容易地回收并循环多达五次,而不会显着损失其催化活性。
  • Preparation of a new DABCO-based ionic liquid [H 2 -DABCO][H 2 PO 4 ] 2 } and its application in the synthesis of tetrahydrobenzo[ b ]pyran and pyrano[2,3- d ]pyrimidinone derivatives
    作者:Farhad Shirini、Mohaddeseh Safarpoor Nikoo Langarudi、Nader Daneshvar
    DOI:10.1016/j.molliq.2017.03.063
    日期:2017.5
    A new acidic ionic liquid, 1,4-diazabicyclo[2.2.2]octane-1,4-diium dihydrogen phosphate [H2-DABCO][H2PO4]2}, was prepared in a quick and straightforward process and characterized by using different methods such as FT-IR, NMR and Mass analysis. Then it was used as a reusable and new catalyst to promote the synthesis of tetrahydrobenzo[b]pyran and pyrano[2,3-d]pyrimidinone derivatives as important biologically
    一种新型的酸性离子液体,1,4-二氮杂双环[2.2.2]辛烷-1,4-磷酸二氢二氢盐[H 2 -DABCO] [H 2 PO 4 ] 2 },可以通过一种快速而直接的方法制备,并通过使用FT-IR,NMR和质量分析等不同方法进行表征。然后,它被用作可重复使用的新催化剂,以促进四氢苯并[ b ]喃和喃并[2,3- d ]嘧啶酮衍生物的合成,它们是重要的生物活性化合物,被用于制药工业。这种适当的方法具有一些优点,例如以高收率生产目标化合物,反应时间短,后处理步骤简单以及使用主要且易于制备的催化剂。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione